Overview
Vertex Pharmaceuticals Incorporated, based in the United States, operates chiefly within the biotechnology industry, focusing on developing and commercializing therapies for serious diseases. Renowned for its significant advances in cystic fibrosis (CF) treatments, Vertex has successfully brought several groundbreaking medications to market that enhance the quality of life for patients with this genetic disorder. Besides its flagship CF products, the company actively expands its research and development pipeline across various other therapeutic categories including sickle cell disease, beta thalassemia, and pain management. Vertex's strategic initiatives aim to leverage its expertise in small molecule drug development to explore potential treatments in additional diseases with significant unmet medical needs.
Basic Stats
The Factor Analysis chart (below right) shows a view of Vertex Pharmaceuticals Incorporated from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 256.30 MM |
| Earnings Date | |
| EPS (TTM) | 14.19 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.18 |
| ROE | 0.25 |
| ROIC | 0.19 |
| CROIC | 0.02 |
| OCROIC | 0.21 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 71.67 /100 |
| Profitability | 83.09 /100 |
| Quality Score | 53.63 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | 20.48 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 7.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Vertex Pharmaceuticals Incorporated. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| No data available. | ||||
